
    
      This is a single-arm multi-center, study in approximately 100 participants with relapsing
      multiple sclerosis who were previously treated with aCD20 mAb therapy. Eligible participants
      will receive open label ofatumumab 20 mg subcutaneous every 4 weeks for 12 months following
      initial loading regimen of 20 milligrams subcutaneous doses on Days 1, 7 and 14. Assessments
      will include but are not limited to Magnetic Resonance Imaging (MRI) assessed for quality by
      central reading center, multiple Patient Reported Outcome measurements and safety
      assessments..Participants that do not continue onto commercial ofatumumab or another therapy
      within one month of the End of Study Visit must continue into the safety Follow Up phase,
      consisting of every 3 month visits including B cell monitoring until they are able to start
      on commercial ofatumumab or switch to another therapy or until their B cells are repleted
      defined as a B cell concentration greater than the individual participant's baseline value or
      greater than the lower limit of normal. All participants will have a safety follow-up phone
      call at 30 days post study.
    
  